A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety, efficacy and bone changes with combination therapy of
intravenous (IV) infused DKN-01 and lenalidomide/dexamethasone, versus lenalidomide and
dexamethasone in relapsed or refractory multiple myeloma (MM) patients